Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Return on Sales (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Return on Sales for 15 consecutive years, with 29.69% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 4835.0% to 29.69% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 77.33% through Dec 2025, down 1097.0% year-over-year, with the annual reading at 77.33% for FY2025, 1087.0% down from the prior year.
  • Return on Sales hit 29.69% in Q4 2025 for Cardiff Oncology, up from 93.82% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 29.69% in Q4 2025 to a low of 149.65% in Q1 2022.
  • Historically, Return on Sales has averaged 88.73% across 5 years, with a median of 79.71% in 2021.
  • Biggest five-year swings in Return on Sales: surged 9639bps in 2024 and later plummeted -7450bps in 2025.
  • Year by year, Return on Sales stood at 71.62% in 2021, then decreased by -2bps to 73.38% in 2022, then increased by 19bps to 59.77% in 2023, then crashed by -31bps to 78.05% in 2024, then soared by 62bps to 29.69% in 2025.
  • Business Quant data shows Return on Sales for CRDF at 29.69% in Q4 2025, 93.82% in Q3 2025, and 115.22% in Q2 2025.